ANALYST RATINGS

Freedom Broker Upgrades Kinross Gold Rating

Freedom Broker upgrades Kinross Gold to Buy with $38 target. Strong cash flow and record margins drive the upgrade.

ByWilliam Thomas- Senior Editor

Yesterday / 13:32|Last updated: Yesterday / 13:35

0

0

Freedom Broker Upgrades Kinross Gold Rating — Photo: Prepared by Bond.az

Freedom Broker upgraded Kinross Gold (NYSE:KGC) to Buy from Hold and raised the price target to $38.00 from $13.50.

The firm cited Q1 2026 results, with record free cash flow of $837.5 million and operating cash flow of $1.14 billion. Shares have returned 108% over the past year but trade at $28.38.

Analyst Vitaly Kononov noted the company is capturing gold price leverage while holding costs flat. Kinross boasts a perfect Piotroski Score of 9 and strong 24.6% return on assets.

More News

RBC Capital hikes Dominion Resources price target

Yesterday / 20:21

|

381

RBC Capital hikes Dominion Resources price target

RBC Capital raises Dominion price target to $72 on NextEra deal. Sector Perform rating maintained with 7% arbitrage spread.

ANALYST RATINGS →

0

0

BofA raises Candel price target to $9

Yesterday / 20:20

|

884

BofA raises Candel price target to $9

BofA raises Candel price target to $9 after 39% improvement in prostate cancer survival data.

ANALYST RATINGS →

0

0

Roblox rebounds on user growth, Needham says

Yesterday / 18:11

|

808

Roblox rebounds on user growth, Needham says

Needham reiterates Roblox Buy rating amid user growth rebound. Stock has 27% upside to $60 target.

ANALYST RATINGS →

0

0

US Tiger Securities Boosts Baidu Price Target on AI

Yesterday / 17:51

|

287

US Tiger Securities Boosts Baidu Price Target on AI

US Tiger Securities raised Baidu price target to $160 on AI growth. AI revenue now exceeds half of business.

ANALYST RATINGS →

0

0

AMAT and LRCX stocks defended by Lynx

Yesterday / 15:50

|

224

AMAT and LRCX stocks defended by Lynx

Lynx Equity defends AMAT and LRCX stocks with bullish price targets of $540 and $325 respectively.

ANALYST RATINGS →

0

0

Yesterday / 14:45

|

827

DA Davidson Maintains Brunswick Stock Neutral

DA Davidson reaffirms Neutral rating on Brunswick with $76 target. Premium brands strong, value brands weak. Q1 2026 results beat estimates.

ANALYST RATINGS →

0

0

D.A. Davidson Reaffirms Aebi Schmidt on Strong Orders

Yesterday / 14:43

|

834

D.A. Davidson Reaffirms Aebi Schmidt on Strong Orders

D.A. Davidson reaffirms Buy rating on Aebi Schmidt with $15 target. Strong order backlog up 23%. Revenue beats expectations. Get details on Bond.az.

ANALYST RATINGS →

0

0

JPMorgan Reiterates Five Below Stock Rating with $306 Target

Yesterday / 13:01

|

960

JPMorgan Reiterates Five Below Stock Rating with $306 Target

JPMorgan reiterates Overweight rating on Five Below with $306 price target, implying 43% upside potential.

ANALYST RATINGS →

0

0

Elmet Stock Gets Overweight Rating

Yesterday / 11:44

|

685

Elmet Stock Gets Overweight Rating

Cantor Fitzgerald starts Elmet Group with Overweight rating and $20 target. Defense and reshoring trends drive outlook.

ANALYST RATINGS →

0

0

Truist Starts Arcus Biosciences at Buy on RCC Potential

Yesterday / 11:25

|

722

Truist Starts Arcus Biosciences at Buy on RCC Potential

Truist Securities initiates Arcus Biosciences with Buy rating and $35 price target, citing casdatifan's potential in renal cell carcinoma and immunology pipeline.

ANALYST RATINGS →

0

0

Revolution stock buy rating from Truist

Yesterday / 11:24

|

728

Revolution stock buy rating from Truist

Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.

ANALYST RATINGS →

0

0

H.C. Wainwright Upgrades Circle Stock to Buy

Yesterday / 10:53

|

220

H.C. Wainwright Upgrades Circle Stock to Buy

H.C. Wainwright upgrades Circle Internet Group stock to Buy, citing ARC token presale and Arc network potential. Price target raised to $150.

ANALYST RATINGS →

0

0

...